NCT01795391

Brief Summary

Intravascular devices in intensive care units are often associated to complications. The investigators estimate that 23.5% of catheters placed and used in intensive care are subject to at least one complication; the goal is to demonstrate the effectiveness of the new Tegaderm ™ IV Advanced dressings to achieve a decrease of 35% in the number of complications associated with intravascular catheters in intensive care.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
685

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2012

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

February 18, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 20, 2013

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2013

Completed
Last Updated

January 22, 2014

Status Verified

January 1, 2014

Enrollment Period

1.1 years

First QC Date

February 18, 2013

Last Update Submit

January 20, 2014

Conditions

Keywords

PreventionDressingsCatheters

Outcome Measures

Primary Outcomes (1)

  • Number of catheters presenting any kind of complications.

    From the insertion of the catheter to its removal, an average time frame thant can go up to 4 weeks.

Secondary Outcomes (1)

  • Number of infections related to poor adherent dressings.

    From the insertion of the catheter to its removal, an average time frame thant can go up to 4 weeks.

Other Outcomes (2)

  • Number of participants presenting allergic adverse events.

    From the insertion of the catheter to its removal, an average time frame thant can go up to 4 weeks.

  • Cost of each dressing type strategy.

    From the insertion of the catheter to its removal, an average time frame thant can go up to 4 weeks.

Study Arms (2)

Tegaderm HP

Patients whose intravasculare devices dressings are made exclusevely with Tegaderm HP dressings.

Advanced

Patients whose intravasculare devices dressings are made exclusevely with Advanced dressings

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients hospitalised in the Medical ICU and requiring an intravascular device during hospitalisation (peripheral or central)

You may qualify if:

  • Patients over 18 years with a central venous catheter, an arterial catheter, a hemodialysis catheter, a Swan Ganz catheter or a peripheral catheter inserted in the ICU or within the 24 before their arrival at the ICU in another ICU setting.
  • Patients benefiting from the social security protection.

You may not qualify if:

  • Patients under 18 years of age,
  • Patients having known allergy or sensitivity to adhesive dressing materials

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital of Grenoble, Medical Intensive Care Unit

Grenoble, Isère, 38043, France

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 18, 2013

First Posted

February 20, 2013

Study Start

October 1, 2012

Primary Completion

November 1, 2013

Study Completion

November 1, 2013

Last Updated

January 22, 2014

Record last verified: 2014-01

Locations